Congressional spending plan: What’s in it for healthcare, and what isn’t
Chief Healthcare Executive December 21, 2024
STAT+: Biotech companies detail emerging efforts to ease ‘conditioning’ before genetic treatments
STAT December 9, 2024
The procedures, highlighted at ASH meeting, could help widen access
SAN DIEGO — The approval one year ago of two genetic medicines for sickle cell disease, including the first therapy powered by CRISPR gene editing, was a milestone for people living with a debilitating blood disease long neglected by the medical establishment. But access to the near-curative treatments has been slowed by their high...
Today's Sponsors
Today's Sponsor